These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34358459)

  • 1. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
    Mol Cell; 2021 Aug; 81(15):3227. PubMed ID: 34358459
    [No Abstract]   [Full Text] [Related]  

  • 2. Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.
    Kawahara N; Ogawa K; Nagayasu M; Kimura M; Sasaki Y; Kobayashi H
    Biomed Rep; 2017 Nov; 7(5):391-399. PubMed ID: 29109859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
    Zhu H; Wei M; Xu J; Hua J; Liang C; Meng Q; Zhang Y; Liu J; Zhang B; Yu X; Shi S
    Mol Cancer; 2020 Mar; 19(1):49. PubMed ID: 32122376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filling in the gaps in PARP inhibitor-induced synthetic lethality.
    Paes Dias M; Jonkers J
    Mol Cell Oncol; 2021; 8(6):2010512. PubMed ID: 35419484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S
    Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways: targeting PARP in cancer treatment.
    Do K; Chen AP
    Clin Cancer Res; 2013 Mar; 19(5):977-84. PubMed ID: 23269547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    Layman RM; Arun B
    Cancer J; 2021 Jan-Feb 01; 27(1):67-75. PubMed ID: 33475295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
    Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
    Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
    Wang Y; Zuo M; Jin H; Lai M; Luo J; Cheng Z
    J Recept Signal Transduct Res; 2021 Jun; 41(3):304-311. PubMed ID: 32814472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA mutations in pancreatic cancer and progress in their targeting.
    Alkassis S; Yazdanpanah O; Philip PA
    Expert Opin Ther Targets; 2021 Jul; 25(7):547-557. PubMed ID: 34289788
    [No Abstract]   [Full Text] [Related]  

  • 16. A review on mechanisms of resistance to PARP inhibitors.
    Desai C; Pathak A; Limaye S; Maniar V; Joshi A
    Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
    Keung MYT; Wu Y; Vadgama JV
    J Clin Med; 2019 Mar; 8(4):. PubMed ID: 30934991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.
    Incorvaia L; Passiglia F; Rizzo S; Galvano A; Listì A; Barraco N; Maragliano R; Calò V; Natoli C; Ciaccio M; Bazan V; Russo A
    Oncotarget; 2017 Apr; 8(14):23891-23904. PubMed ID: 28055979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP Inhibitors in Epithelial Ovarian Cancer.
    Taylor KN; Eskander RN
    Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the safety of olaparib for treating ovarian cancer.
    Cottrell K; Clark CL; Penson RT
    Expert Opin Drug Saf; 2022 Apr; 21(4):447-451. PubMed ID: 35212587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.